Royalty Pharma plc

What they do

Royalty Pharma acquires royalties on commercial and development-stage biopharmaceutical products, entitling it to payments based on product sales. Its portfolio includes royalties on more than 35 commercial products, such as Vertex's Trikafta and Alyftrek, GSK's Trelegy, and Biogen's Tysabri, plus 20 development-stage candidates. The company generates Portfolio Receipts from royalty receipts and milestones, using that cash to fund new investments.

Revenue drivers

• Royalty Receipts — Variable payments based on sales of products in the portfolio, net of contractual payments to legacy non-controlling interests. Q2 2026 Royalty Receipts were $768 million, up 14% year-over-year.
• Milestones and other contractual receipts — Sales-based or regulatory milestone payments and fixed contractual receipts, net of legacy non-controlling interests. In Q2 2026, these were lower, causing Portfolio Receipts growth of 6% to $773 million.
• Key products driving growth — Q2 2026 Royalty Receipts growth was driven by Tremfya, Voranigo, Imdelltra, and Evrysdi.
• Development-stage pipeline — 19 potential therapies as of August 2026, including a recently acquired royalty on AstraZeneca's cliramitug for transthyretin amyloidosis with cardiomyopathy.

Recent performance

For Q2 2026, Royalty Pharma reported Portfolio Receipts of $773 million, up 6%, and Royalty Receipts of $768 million, up 14%. Net cash provided by operating activities was $728 million, up 100% from $364 million in Q2 2025. Adjusted EBITDA was $736 million, up 16%. Quarterly revenue has risen from $609.3M (Sep 2025) to $674.1M (Jun 2026). Full-year 2025 revenue was $2.38B with net income of $770.9M.

Strategy

The company focuses on high-quality therapies addressing significant unmet patient needs, using a selective investment approach and rigorous due diligence. In 2025, it announced transactions with $4.7 billion total potential value and deployed $2.6 billion of cash. In 2026 through August 4, it announced $1.7 billion in transactions and deployed $1.1 billion. The internalization transaction completed on May 16, 2025, eliminating the management fee. The pipeline expansion includes the AstraZeneca cliramitug royalty acquisition in July 2026.

Risks

• Sales dependence on third-party products — Royalty receipts are directly tied to sales of products controlled by other companies, which are outside Royalty Pharma's control.
• Development-stage uncertainties — Acquiring interests in development-stage candidates carries risks of clinical failure, regulatory non-approval, or commercial underperformance.
• Leverage and capital deployment risk — The company uses leverage to fund acquisitions, and its long-term debt was $8.58B as of June 30, 2026, exposing it to interest rate and refinancing risks.
• Market and regulatory risks — Government regulation of the biopharmaceutical industry, interest rate fluctuations, foreign exchange changes, and inflation could adversely affect royalty receipts.

Outlook

Management raised full-year 2026 Portfolio Receipts guidance to $3,400-$3,500 million, implying Royalty Receipts growth of 7-10%. Interest paid is expected to be $350-$360 million. The company expects operating and professional costs to decrease as a percentage of Portfolio Receipts to 5.5-6.5%, down from 8.9% in 2025, due to the internalization. The guidance excludes future transactions and assumes a +1% foreign exchange tailwind.